{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:59:12Z","timestamp":1785293952079,"version":"3.55.0"},"reference-count":28,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Clinical Research Special Fund of the Chinese Society of Cardiology","award":["CSCF2022B04"],"award-info":[{"award-number":["CSCF2022B04"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,7,14]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Statin therapy is associated with an increased risk of dysglycaemia and new-onset type 2 diabetes, which compromises patient adherence. Ursodeoxycholic acid (UDCA), a hepatoprotective drug, has shown potential for improving glycaemic control, but its role in preventing statin-induced dysglycaemia remains unexplored in prospective randomised trials, particularly in a primary prevention setting. This trial aims to determine whether UDCA coadministration can prevent statin-induced impairment of glucose tolerance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is an investigator-initiated, prospective, double-blind, randomised, placebo-controlled trial. A total of 128 participants with newly diagnosed hyperlipidaemia and no history of diabetes or cardiovascular events will be enrolled. Participants will be randomly assigned (1:1) to receive either atorvastatin (20 mg\/day) plus UDCA (500 mg\/day) or atorvastatin plus a matching placebo for 180 days. The primary outcome is the difference in glycated haemoglobin (HbA1c) absolute change from baseline to Day 180 between the intervention and control groups. The secondary outcomes are the difference in the absolute change of cardiometabolic risk factors and body composition between the intervention and control groups from baseline to Day 180. Safety outcomes include adverse events, serious adverse events, abnormal vital signs and abnormal laboratory parameters from baseline to Day 180. Data will be analysed according to the ITT principle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study has been approved by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University (No. XJTU1AF2023LSK-149-02). The study findings will be disseminated through peer-reviewed journals, symposiums and conference presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial \" xlink:href=\"NCT06684106\">NCT06684106<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-117417","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:30:09Z","timestamp":1785292209000},"page":"e117417","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of ursodeoxycholic acid on statin-induced impaired glucose tolerance: study protocol for a randomized controlled trial"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06684106","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06684106","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3589-3043","authenticated-orcid":false,"given":"Yue","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Radiology, First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7030-2889","authenticated-orcid":false,"given":"Jianqing","family":"She","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuyi","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0084-2510","authenticated-orcid":false,"given":"Yue","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2026072805201195000_16.7.e117417.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.04.004"},{"key":"2026072805201195000_16.7.e117417.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03392-8"},{"key":"2026072805201195000_16.7.e117417.3","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1007\/s11427-025-2948-y","article-title":"Global burden of atherosclerotic cardiovascular disease attributed to lifestyle and metabolic risks","volume":"68","author":"Xu","year":"2025","journal-title":"Sci China Life Sci"},{"key":"2026072805201195000_16.7.e117417.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-018-0119-4"},{"key":"2026072805201195000_16.7.e117417.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad191"},{"key":"2026072805201195000_16.7.e117417.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"2026072805201195000_16.7.e117417.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"2026072805201195000_16.7.e117417.8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-8587(24)00040-8","article-title":"Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026072805201195000_16.7.e117417.9","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110184"},{"key":"2026072805201195000_16.7.e117417.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01303-5"},{"key":"2026072805201195000_16.7.e117417.11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3748\/wjg.v27.i10.959","article-title":"Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"27","author":"Nadinskaia","year":"2021","journal-title":"World J Gastroenterol"},{"key":"2026072805201195000_16.7.e117417.12","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/4187796","article-title":"Beneficial Effects of Ursodeoxycholic Acid on Metabolic Parameters and Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blind, Placebo-Controlled Clinical Study","volume":"2024","author":"Laki\u0107","year":"2024","journal-title":"J Diabetes Res"},{"key":"2026072805201195000_16.7.e117417.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.08.030"},{"key":"2026072805201195000_16.7.e117417.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.12.027"},{"key":"2026072805201195000_16.7.e117417.15","doi-asserted-by":"crossref","DOI":"10.1186\/2193-1801-2-20","article-title":"Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects","volume":"2","author":"Murakami","year":"2013","journal-title":"Springerplus"},{"key":"2026072805201195000_16.7.e117417.16","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1210\/jc.2018-02804","article-title":"Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis","volume":"104","author":"Mezza","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026072805201195000_16.7.e117417.17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.26599\/1671-5411.2023.09.008","article-title":"2023 China Guidelines for Lipid Management","volume":"20","author":"Li","year":"2023","journal-title":"J Geriatr Cardiol"},{"key":"2026072805201195000_16.7.e117417.18","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.15829\/1560-4071-2020-3826","article-title":"2019 ESC\/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"25","author":"Mach","year":"2019","journal-title":"Russ J Cardiol"},{"key":"2026072805201195000_16.7.e117417.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"2026072805201195000_16.7.e117417.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.13044"},{"key":"2026072805201195000_16.7.e117417.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3528-5"},{"key":"2026072805201195000_16.7.e117417.22","doi-asserted-by":"crossref","DOI":"10.1080\/19382014.2025.2479906","article-title":"Atorvastatin enhances LDL receptor-mediated LDL-C uptake and modulates PCSK9 protein expression in pancreatic \u03b2-cells","volume":"17","author":"Zhang","year":"2025","journal-title":"Islets"},{"key":"2026072805201195000_16.7.e117417.23","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1007\/s00125-025-06441-3","article-title":"Duration and type of statin use and long-term risk of type 2 diabetes among men and women with hypercholesterolaemia: findings from three prospective cohorts","volume":"68","author":"Zhang","year":"2025","journal-title":"Diabetologia"},{"key":"2026072805201195000_16.7.e117417.24","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/eurjpc\/zwaf237","article-title":"Review of strategies to improve adherence to lipid-lowering therapy in the primary prevention of cardiovascular disease","volume":"32","author":"Whitmore","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026072805201195000_16.7.e117417.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100700","article-title":"Statin Adherence and Effects on Outcome in Premature Coronary Artery Disease","volume":"2","author":"Naqvi","year":"2023","journal-title":"JACC Adv"},{"key":"2026072805201195000_16.7.e117417.26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/eurheartj\/ehad831","article-title":"Celebrating the 90th birthday of the scientist who discovered statins: Akira End\u014d","volume":"45","author":"Surma","year":"2024","journal-title":"Eur Heart J"},{"key":"2026072805201195000_16.7.e117417.27","doi-asserted-by":"crossref","unstructured":"Halili A , Eroglu TE , Torp-Pedersen C , et al . Statin use for primary prevention of cardiovascular disease among apparently healthy adults. Eur J Prev Cardiol 2025:zwaf357. doi:10.1093\/eurjpc\/zwaf357","DOI":"10.1093\/eurjpc\/zwaf357"},{"key":"2026072805201195000_16.7.e117417.28","doi-asserted-by":"crossref","first-page":"111589","DOI":"10.1016\/j.diabres.2024.111589","article-title":"International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes","volume":"209","author":"Bergman","year":"2024","journal-title":"Diabetes Res Clin Pract"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-117417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:30:12Z","timestamp":1785292212000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-117417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,28]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjopen-2026-117417"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-117417","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}